Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases

A Kalela; R Laaksonen; T Lehtimäki; T A Koivu; M Höyhtyä; T Janatuinen; P Pöllänen; R Vesalainen; P Saikku; J Knuuti; S T Nikkari

doi:10.1016/s0002-9149(01)01616-2

Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases

Am J Cardiol. 2001 Jul 15;88(2):173-5, A6. doi: 10.1016/s0002-9149(01)01616-2.

Authors

A Kalela¹, R Laaksonen, T Lehtimäki, T A Koivu, M Höyhtyä, T Janatuinen, P Pöllänen, R Vesalainen, P Saikku, J Knuuti, S T Nikkari

Affiliation

¹ Department of Medical Biochemistry, University of Tampere Medical School, Tampere, Finland.

PMID: 11448418
DOI: 10.1016/s0002-9149(01)01616-2

Abstract

Pravastatin decreases serum MMP-9 concentration in clinically healthy men. This may reflect reduction of nonsymptomatic chronic arterial inflammation.

Publication types

Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anticholesteremic Agents / pharmacology
Anticholesteremic Agents / therapeutic use*
Double-Blind Method
Genotype
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / drug therapy*
Hypercholesterolemia / enzymology
Male
Matrix Metalloproteinase 9 / blood*
Matrix Metalloproteinase 9 / drug effects
Matrix Metalloproteinase 9 / genetics
Polymorphism, Genetic
Pravastatin / pharmacology
Pravastatin / therapeutic use*

Substances

Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Matrix Metalloproteinase 9
Pravastatin